Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

When news breaks, you need to understand what actually matters. At Vox, our mission is to help you make sense of the world — and that work has never been more vital. But we can’t do it on our own. We ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Samantha Schoech and Mari Uyehara The clock is ticking to buy Christmas gifts, ...